This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to Decline
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Soars 5.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Down 48.4% in 4 Weeks, Here's Why Zymeworks Inc. (ZYME) Looks Ripe for a Turnaround
by Zacks Equity Research
Zymeworks Inc. (ZYME) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bank on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try a different approach? Tap five stocks with increasing P/E ratios such as MEDIFAST (MED), JAKKS Pacific (JAKK), Asbury Automotive Group (ABG), Zymeworks (ZYME) and Polaris (PII).
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks
by Zacks Equity Research
RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Zymeworks Inc. (ZYME) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -5.93% and -50.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Zymeworks Inc. (ZYME) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks (ZYME) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Zymeworks (ZYME) has been struggling lately, but the selling pressure may be coming to an end soon.
Here's Why Zymeworks Inc. (ZYME) is Poised for a Turnaround After Losing 24.1% in 4 Weeks
by Zacks Equity Research
Zymeworks Inc. (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
New Strong Sell Stocks for August 10th
by Zacks Equity Research
THS, ZYME, NTRA, LAWS, and INSW have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2021
Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -23.58% and -75.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zymeworks Inc. (ZYME) Q2 Earnings Expected to Decline
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 14.71% and -90.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zymeworks Inc. (ZYME) Q1 Earnings Expected to Decline
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Zymeworks (ZYME) Stock?
by Zacks Equity Research
Investors need to pay close attention to Zymeworks (ZYME) stock based on the movements in the options market lately.